IBDoc® has now been on the market for over 2 years and it is transforming the way IBD patients manage their disease. IBDoc® is used by over a thousand patients in more than 15 countries and we now support 20 languages with Hebrew as the latest addition. BÜHLMANN as the only calprotectin company has been able
- info@buhlmannlabs.ch
- +41 61 487 12 12
News
Sensitive Screening for anti-neural antibodies is a key step to identify autoimmune peripheral neuropathies. The new Neuroimmunology flyer explains why BÜHLMANN GanglioCombiTM MAG ELISA is the most sensitive screening for anti-Ganglioside and -MAG antibodies in one single step and why anti-MAG antibody ELISA is the gold standard. Click here to get access to the new
Inflammatory Bowel Disease (IBD) is a chronic inflammatory disease of the gut, which presents with periods of inflammatory activity (flares) and quiescent phases (remission) as can be seen in many chronic diseases. IBD includes several different diseases; the two most important ones are Ulcerative Colitis (UC), with inflammation localized mostly in the colon, and Crohn’s Disease (CD)
New BÜHLMANN fCAL® ELISA Citation: The team around James Turvill has proposed a highly useful care pathway for monitoring Crohn’s Disease patients. The care pathway offers a very high positive predictive value for the detection of patients with potential flare-ups of their disease while safely identifying those patients in which the therapy could be stepped down. Turvill J, Rook L, Rawle
Social Links